Trials / Conditions / ER-Positive HER2-Negative Breast Cancer
ER-Positive HER2-Negative Breast Cancer
5 registered clinical trials studyying ER-Positive HER2-Negative Breast Cancer.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 NCT05364255 | AstraZeneca | Phase 1 |
| Unknown | A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Nega NCT04993430 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression ( NCT04964934 | AstraZeneca | Phase 3 |
| Active Not Recruiting | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positi NCT04711252 | AstraZeneca | Phase 3 |
| Unknown | Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women NCT01709370 | Organisation for Oncology and Translational Research | Phase 2 |